Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137134 | 0.78 | RAF1 (0.42) | RAF1OPRK1KCNH2BRAFP2RX3 | |
| SCHEMBL4155509 | 0.78 | PARP10 (0.51) | RAF1OPRK1KCNH2BRAFKDR | |
| SCHEMBL177841 | 0.76 | PARP10 (0.54) | RAF1OPRK1KCNH2BRAFP2RX3 | |
| SCHEMBL4369342 | 0.76 | PARP10 (0.54) | RAF1BRAFP2RX3KDRCYP4F2 | |
| SCHEMBL11206449 | 0.76 | OPRK1 (0.44) | RAF1OPRK1KCNH2BRAFP2RX3 | |
| SCHEMBL6273015 | 0.75 | RAF1 (0.50) | RAF1OPRK1KCNH2BRAFP2RX3 | |
| SCHEMBL29757282 | 0.75 | P2RX3 (0.53) | RAF1P2RX3GRM5 | |
| SCHEMBL257959 | 0.75 | RAF1 (0.50) | RAF1BRAFP2RX3KDR | |
| SCHEMBL30079970 | 0.75 | GRM5 (0.59) | GRM5 | |
| SCHEMBL23913769 | 0.75 | P2RX3 (0.53) | RAF1P2RX3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RAF1 140/4885OPRK1 3631/4885KCNH2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.